Open Access Open Access  Restricted Access Subscription or Fee Access

A case report of satisfactory post-left knee replacement pain control after switching from oxycodone to buprenorphine

Shuo Qiu, MD, Sachinder Vasudeva, MD


This case report demonstrates using buprenorphine 32 mg to achieve adequate pain control after a total knee replacement. The patient stopped buprenorphine 48 hours before surgery. He was prescribed 150 tablets of oxycodone 5 mg. After finishing oxycodone, he experienced significant pain that was relieved by 32 mg of buprenorphine daily. Urine drug screens were negative perioperatively. Patients with opioid use disorder require careful discharge planning to avoid opioid relapses or misuses of pain medications. Buprenorphine offers many unique advantages in acute pain control, including lower risk of respiratory depression, abuse potential, and lower risk of nephrotoxicity.


acute pain, buprenorphine, opioid use disorder, post-operative

Full Text:



Chen KY, Chen L, Mao J: Buprenorphine–naloxone therapy in pain management. Anesthesiol J Am Soc Anesthesiol. 2014; 120(5): 1262-1274. DOI: 10.1097/ALN.0000000000000170.

Bettinger JJ, Pharm D, Fudin J, et al.: Buprenorphine and surgery: What's the protocol? Practical pain management. Available at Accessed July 31, 2020.

Anderson TA, Quaye ANA, Ward EN, et al.: To stop or not, that is the question acute pain management for the patient on chronic buprenorphine. Anesthesiol J Am Soc Anesthesiol. 2017; 126(6): 1180-1186. DOI: 10.1097/ALN.0000000000001633.

Likar R: Transdermal buprenorphine in the management of persistent pain—Safety aspects. Ther Clin Risk Manag. 2006; 2(1): 115-125.

Dankiewicz EH: Use of the low-dose buprenorphine patch: A response. J Palliat Med. 2014; 17(4): 379-380. DOI: 10.1089/jpm.2014.9438.

Aiyer R, Gulati A, Gungor S, et al.: Treatment of chronic pain with various buprenorphine formulations: A systematic review of clinical studies. Anesth Analg. 2018; 127(2): 529-538. DOI: 10.1213/ANE.0000000000002718.

Neumann AM, Blondell RD, Hoopsick RA, et al.: Randomized clinical trial comparing buprenorphine/naloxone and methadone for the treatment of patients with failed back surgery syndrome and opioid addiction. J Addict Dis. 2020; 38(1): 33-41. DOI: 10.1080/10550887.2019.1690929.

Veazie S, Mackey K, Peterson K, et al.: Managing acute pain in patients taking medication for opioid use disorder: A rapid review. J Gen Intern Med. 2020; 35(Suppl. 3): 945-953. DOI: 10.1007/s11606-020-06256-5.

Xu X, Xie L, Liu H, et al.: Transdermal buprenorphine patch versus oral celecoxib for pain management after total knee arthroplasty: An open-label, randomized controlled trial. Orthop Traumatol Surg Res OTSR. 2020; 106(5): 915-919. DOI: 10.1016/j.otsr.2020.04.010.

Li W-M, Li F-D, Xu H, et al.: Analgesic impact of buprenorphine transdermal patch in total hip arthroplasty. Medicine (Baltimore). 2020; 99(24). DOI: 10.1097/MD.0000000000020405.

Thakrar S, Lee J, Martin CE, et al.: Buprenorphine management: A conundrum for the anesthesiologist and beyond—A one-act play. Reg Anesth Pain Med. 2020; 45(8): 656-659. DOI: 10.1136/rapm-2020-101294.

Malan SH, Bailey CH, Khurmi N: Perioperative management of a patient taking Suboxone® at the time of ambulatory surgery. Case Rep Anesth. 2020. DOI: 10.1155/2020/5628348.

Mehta D, Thomas V, Johnson J, et al.: Continuation of buprenorphine to facilitate postoperative pain management for patients on buprenorphine opioid agonist therapy. Pain Physician. 2020; 23(2): E163-E174.

Londhe S, Patwardhan M, Shah R, et al.: Efficacy and safety of buprenorphine transdermal patch for immediate postoperative analgesia after total knee arthroplasty surgery. J Arthroplasty. 2020; 35(6S): S178-S181. DOI: 10.1016/j.arth.2020.02.015.

Ward EN, Quaye AN-A, Wilens TE: Opioid use disorders: Perioperative management of a special population. Anesth Analg. 2018; 127(2): 539-547. DOI: 10.1213/ANE.0000000000003477.

Kunkel FA, Luke MD, Md C: Preparing patients taking sublingual buprenorphine to treat addiction for surgery. Practical pain management. Available at Accessed July 31, 2020.

Lembke A, Ottestad E, Schmiesing C: Patients maintained on buprenorphine for opioid use disorder should continue buprenorphine through the perioperative period. Pain Med. 2019; 20(3): 425-428. DOI: 10.1093/pm/pny019.

Khanna IK, Pillarisetti S: Buprenorphine—An attractive opioid with underutilized potential in treatment of chronic pain. J Pain Res. 2015; 8: 859-870. DOI: 10.2147/JPR.S85951.

Böger RH: Renal impairment: A challenge for opioid treatment? The role of buprenorphine. Palliat Med. 2006; 20 (Suppl. 1): S17-S23.

Filitz J, Griessinger N, Sittl R, et al.: Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain. 2006; 10(8): 743-748. DOI: 10.1016/j.ejpain.2005.12.001.

Buresh M, Ratner J, Zgierska A, et al. Treating perioperative and acute pain in patients on buprenorphine: Narrative literature review and practice recommendations. J Gen Intern Med. 2020. DOI: 10.1007/s11606-020-06115-3.

Preoperative Opioid Taper Initiative: Available at Accessed December 17, 2020.

Kornfeld H, Manfredi L: Effectiveness of full agonist opioids in patients stabilized on buprenorphine undergoing major surgery: A case series. Am J Ther. 2010; 17(5): 523-528. DOI: 10.1097/MJT.0b013e3181be0804.

Macintyre PE, Russell RA, Usher KAN, et al.: Pain relief and opioid requirements in the first 24 hours after surgery in patients taking buprenorphine and methadone opioid substitution therapy. Anaesth Intensive Care. 2013; 41(2): 222-230. DOI: 10.1177/0310057X1304100212.

Acampora GA, Nisavic M, Zhang Y: Perioperative buprenorphine continuous maintenance and administration simultaneous with full opioid agonist: Patient priority at the interface between medical disciplines. J Clin Psychiatry. 2020; 81. DOI: 10.4088/JCP.19com12810.

Clinard F, Sgro C, Bardou M, et al.: Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case/non-case study from the French pharmacovigilance system database. Eur J Clin Pharmacol. 2004; 60(4): 279-283. DOI: 10.1007/s00228-004-0761-0.



  • There are currently no refbacks.